Status:
COMPLETED
Efficacy and Safety of Lumiracoxib in Patients With Knee Osteoarthritis (OA).
Lead Sponsor:
Novartis
Conditions:
Osteoarthritis, Knee
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study will investigate the efficacy and safety of lumiracoxib in patients with primary knee osteoarthritis (OA).
Eligibility Criteria
Inclusion
- Primary osteoarthritis of knee (confirmed by American College of Rheumatology \[ACR\] criteria).
- Requirement of regular non-steroidal anti-inflammatory drug (NSAID) therapy.
Exclusion
- Evidence of active gastrointestinal ulceration within 12 months prior to the screening visit or history of active gastrointestinal bleeding within the previous 5 years.
- Known hypersensitivity to analgesics, antipyretics, or NSAIDS (including celecoxib).
- Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
1464 Patients enrolled
Trial Details
Trial ID
NCT00366938
Start Date
September 1 2003
Last Update
May 21 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey, United States, 07936